Tearing Down The Goalposts: What’s Next For US FDA Diabetes Guidelines?
Executive Summary
Advisory committee discussion of cardiovascular safety standards for type 2 diabetes therapies was a friendly, collegial event with broad agreement on how FDA’s diabetes guidelines can be improved. Unfortunately, the panel split down the middle on the critical question for FDA.